Febrile Neutropenia Market, By Etiology (Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, and Viral Infections), By Treatment, By Risk Factors, By Diagnostic Methods, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4541
|
Published Date
December 2025
|
Pages
355
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Febrile Neutropenia Market size was valued at US$ 10,789.45 Million in 2024, expanding at a CAGR of 4.2% from 2025 to 2032.
Febrile Neutropenia refers to the rapid onset of fever in patients with abnormally low neutrophil counts, most commonly resulting from chemotherapy-induced bone marrow suppression. It is a high-acuity medical emergency requiring immediate antimicrobial therapy to prevent severe infections, sepsis, and related complications. The global market for febrile neutropenia management is expanding, driven by rising oncology caseloads and the increasing adoption of risk-stratified treatment protocols. Innovations such as long-acting granulocyte-colony stimulating factor (G-CSF) formulations, rapid diagnostic panels, and advanced infection-control algorithms are reshaping clinical practice and improving patient outcomes.
However, the market faces ongoing challenges, including high biologic drug costs, growing antimicrobial resistance, and reimbursement constraints, particularly in resource-limited regions. Despite these hurdles, opportunities are emerging through precision supportive-care strategies, point-of-care diagnostics, and AI-enabled infection-prediction tools, which are transitioning from pilot programs to broader clinical adoption. These advancements are poised to transform febrile neutropenia management, enabling faster, safer, and more cost-effective care for patients worldwide.
Febrile Neutropenia Market- Market Dynamics
Rising Global Cancer Burden
The rising global cancer burden is the primary driver of growth in the febrile neutropenia (FN) market. According to the World Health Organization (WHO), the number of new cancer cases worldwide is projected to increase significantly, driven by an aging population and heightened exposure to risk factors such as tobacco use, obesity, and environmental pollution. As more patients undergo myelosuppressive chemotherapy and other aggressive cancer treatments, the incidence of neutropenia—and consequently febrile neutropenia—rises. Studies indicate that FN affects up to 30% of patients receiving chemotherapy. This growing patient population is driving heightened demand for FN management solutions, including prophylactic therapies, long-acting granulocyte-colony stimulating factors (G-CSFs), and rapid diagnostic tools. As cancer prevalence continues to climb globally, the need for effective FN prevention, monitoring, and treatment solutions will expand correspondingly, establishing cancer incidence as the central growth engine for the FN market.
Febrile Neutropenia Market- Segmentation Analysis:
The Global Febrile Neutropenia Market is segmented on the basis of Etiology, Treatment, Risk Factors, Diagnostic Methods, and Region.
The febrile neutropenia (FN) market, based on etiology, is segmented into gram-negative bacteria, gram-positive bacteria, fungal infections, and viral infections. Gram-negative bacteria are considered the primary clinical cause of FN due to their high virulence and rising antibiotic resistance. Common pathogens include Escherichia coli, Klebsiella spp., and Pseudomonas aeruginosa, which remain the leading culprits in bloodstream infections among immunocompromised patients, particularly oncology patients. According to the Centers for Disease Control and Prevention (CDC, 2023), gram-negative infections account for more than 40% of healthcare-associated bloodstream infections, underscoring the critical need for timely intervention. The rapid progression of these infections into sepsis, coupled with high mortality risk, has heightened demand for broad-spectrum antibiotics. Additionally, the emergence of beta-lactamase-producing extended-spectrum beta-lactamases (ESBLs) from Enterobacterales has complicated treatment strategies, driving the need for new antibiotics, rapid diagnostic tools, and precision antimicrobial stewardship programs in FN management.
In terms of treatment, febrile neutropenia is primarily managed with empirical antibiotic therapy due to the urgent requirement to initiate antimicrobials within 60 minutes of fever onset, as recommended by the Infectious Disease Society of America (IDSA, 2022) and National Comprehensive Cancer Network (NCCN, 2023) guidelines. This critical period, often referred to as the “golden hour,” is essential as FN patients can deteriorate rapidly into septic shock if treatment is delayed. Standard antibiotics include broad-spectrum β-lactams, carbapenems, and anti-pseudomonal agents. The global rise in antimicrobial resistance has prompted hospitals to adopt combination therapies, extended-spectrum antibiotics, and stewardship programs to ensure effective treatment while minimizing resistance. Ongoing innovations, including fast-acting intravenous formulations and high-sensitivity pathogen detection technologies, are expected to further improve outcomes in FN patients, making the empirical therapy segment the cornerstone of care for this vulnerable population.
Febrile Neutropenia Market- Geographical Insights
The febrile neutropenia (FN) treatment market in North America is a high-value yet mature segment, primarily driven by the region’s substantial cancer patient population and access to intensive chemotherapy. In 2022, the United States, Canada, and Mexico collectively reported approximately 2.9 million new cancer cases. In the U.S. alone, the American Cancer Society projects around 2 million new cases and over 611,000 cancer-related deaths in 2024. Patients undergoing myelosuppressive therapies, the majority of whom receive supportive FN prophylaxis, represent a large population at risk for febrile neutropenia.
The market benefits from well-established healthcare infrastructure, strict adherence to guidelines from the Infectious Diseases Society of America (IDSA) and the National Comprehensive Cancer Network (NCCN), and rapid adoption of G-CSF biosimilars and broad-spectrum intravenous antibiotics. These factors enable early intervention and aggressive management of FN cases, improving patient outcomes. Key trends shaping the U.S. FN market include rising antimicrobial resistance, growing adoption of value-based care models, risk-stratified patient management, and outpatient FN treatment pathways supported by rapid molecular diagnostics in oncology and emergency settings.
United States Febrile Neutropenia Market- Country Insights
The United States represents the largest market in North America for febrile neutropenia (FN) treatments and continues to report one of the highest age-adjusted cancer incidence rates globally, at 367 cases per 100,000 population annually. A significant proportion of patients undergo intensive multi-drug chemotherapy, stem cell transplants, and novel targeted or immunotherapeutic regimens, creating a steady population at risk for developing FN. According to the American Cancer Society, approximately 2 million new cancer cases and 611,720 cancer-related deaths are projected in the U.S. in 2024. This underscores sustained demand for FN prophylactic therapies, timely empirical antimicrobial treatments, and comprehensive supportive care.
The U.S. market is further supported by high insurance reimbursement for G-CSFs and other costly injectable products, widespread use of automated sepsis-alert systems, and robust antimicrobial stewardship programs. However, challenges remain, including disparities in access to care due to race, geographic location, and hospital-acquired infections. These factors are driving innovations such as outpatient FN management, oral step-down regimens, and the adoption of predictive analytics to identify and triage high-risk patients earlier in the treatment process.
Febrile Neutropenia Market- Competitive Landscape:
The FN treatment market is highly competitive, with leading pharmaceutical companies including Amneal Pharmaceuticals, AstraZeneca, Aurobindo Pharma, Bayer, BeyondSpring, Biocon Biologics, Biogen, Bristol Myers Squibb, Coherus BioSciences, Eli Lilly, Fresenius Kabi, G1 Therapeutics, GSK, Intas Pharmaceuticals, Johnson & Johnson, Kyowa Kirin, Merck, Novartis, Pfizer, Roche, Sanofi, Spectrum Pharmaceuticals, Teva, and Viatris.
Competition is primarily centered on G-CSFs, long-acting pegfilgrastim formulations, and emerging myeloprotective agents. Key strategies include partnerships with biosimilar developers, expansion of immunotherapy portfolios, and integration of FN-risk-reduction protocols. Biosimilars, such as Biocon’s Fulphila (pegfilgrastim), approved in the U.S., EU, and Canada, offer both price and access competition, while Coherus’ UDENYCA and G1 Therapeutics’ trilaciclib (COSELA) demonstrate innovation in myeloprotective therapy. Leading companies also leverage real-world evidence, strategic alliances, and R&D investments to maintain market share and address unmet needs.
Recent Developments
- August 2025: Intas/Accord acquired UDENYCA from Coherus, enhancing its biosimilar portfolio and establishing a global pegfilgrastim supply chain. The acquisition included sales, supply, manufacturing, and quality teams.
- September 2025: Amgen launched a digital platform to improve patient engagement and adherence to FN treatment protocols, highlighting the company’s focus on patient-centric care and digital transformation.
- August 2025: Roche partnered with a biotechnology firm to develop a novel FN therapy, expected to enter clinical trials in early 2026, demonstrating its commitment to innovation and market expansion.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FEBRILE NEUTROPENIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amneal Pharmaceuticals, Inc.
- AstraZeneca
- Aurobindo Pharma Limited
- Bayer
- Beyond Spring Inc.
- Biocon Biologics Ltd.
- Biogen
- BristolMyers Squibb
- Celgene
- Cellerant Therapeutics, Inc.
- Coherus BioSciences, Inc.
- Eli Lilly and Company
- Fresenius Kabi
- G1 Therapeutics, Inc.
- Gedeon Richter Plc.
- GlaxoSmithKline
- Hanmi Pharmaceutical Co., Ltd.
- Intas Pharmaceuticals Ltd.
- Johnson & Johnson
- Kyowa Kirin Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Partner Therapeutics, Inc.
- Pfizer Inc.
- Roche
- Sanofi
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Others
GLOBAL FEBRILE NEUTROPENIA MARKET, BY ETIOLOGY- MARKET ANALYSIS, 2019 - 2032
- Gram-Negative Bacteria
- Gram-Positive Bacteria
- Fungal Infections
- Viral Infections
GLOBAL FEBRILE NEUTROPENIA MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032
- Empirical Antibiotic Therapy
- Targeted Antibiotic Therapy
- Supportive Care
GLOBAL FEBRILE NEUTROPENIA MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032
- Chemotherapy-Induced Neutropenia
- Transplant-Related Neutropenia
- Genetic Disorders
GLOBAL FEBRILE NEUTROPENIA MARKET, BY DIAGNOSTIC METHODS- MARKET ANALYSIS, 2019 - 2032
- Blood Cultures
- Imaging Tests
- Bone Marrow Aspiration
GLOBAL FEBRILE NEUTROPENIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Febrile Neutropenia Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Febrile Neutropenia Market Snippet by Etiology
2.1.2. Febrile Neutropenia Market Snippet by Treatment
2.1.3. Febrile Neutropenia Market Snippet by Risk Factors
2.1.4. Febrile Neutropenia Market Snippet by Diagnostic Methods
2.1.5. Febrile Neutropenia Market Snippet by Country
2.1.6. Febrile Neutropenia Market Snippet by Region
2.2. Competitive Insights
3. Febrile Neutropenia Key Market Trends
3.1. Febrile Neutropenia Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Febrile Neutropenia Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Febrile Neutropenia Market Opportunities
3.4. Febrile Neutropenia Market Future Trends
4. Febrile Neutropenia Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Febrile Neutropenia Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Febrile Neutropenia Market Landscape
6.1. Febrile Neutropenia Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Febrile Neutropenia Market – By Etiology
7.1. Overview
7.1.1. Segment Share Analysis, By Etiology, 2024 & 2032 (%)
7.1.2. Gram-Negative Bacteria
7.1.3. Gram-Positive Bacteria
7.1.4. Fungal Infections
7.1.5. Viral Infections
8. Febrile Neutropenia Market – By Treatment
8.1. Overview
8.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
8.1.2. Empirical Antibiotic Therapy
8.1.3. Targeted Antibiotic Therapy
8.1.4. Supportive Care
9. Febrile Neutropenia Market – By Risk Factors
9.1. Overview
9.1.1. Segment Share Analysis, By Risk Factors, 2024 & 2032 (%)
9.1.2. Chemotherapy-Induced Neutropenia
9.1.3. Transplant-Related Neutropenia
9.1.4. Genetic Disorders
10. Febrile Neutropenia Market – By Diagnostic Methods
10.1. Overview
10.1.1. Segment Share Analysis, By Diagnostic Methods, 2024 & 2032 (%)
10.1.2. Blood Cultures
10.1.3. Imaging Tests
10.1.4. Bone Marrow Aspiration
11. Febrile Neutropenia Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Febrile Neutropenia Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Febrile Neutropenia Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Febrile Neutropenia Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Febrile Neutropenia Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
11.6.1. Overview
11.6.2. Febrile Neutropenia Key Manufacturers in Middle East and Africa
11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. Middle East and Africa Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.6.6. Middle East and Africa Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.6.7. Middle East and Africa Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Febrile Neutropenia Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Amneal Pharmaceuticals, Inc.
12.2.2. AstraZeneca
12.2.3. Aurobindo Pharma Limited
12.2.4. Bayer
12.2.5. BeyondSpring Inc.
12.2.6. Biocon Biologics Ltd.
12.2.7. Biogen
12.2.8. BristolMyers Squibb
12.2.9. Celgene
12.2.10. Cellerant Therapeutics, Inc.
12.2.11. Coherus BioSciences, Inc.
12.2.12. Eli Lilly and Company
12.2.13. Fresenius Kabi
12.2.14. G1 Therapeutics, Inc.
12.2.15. Gedeon Richter Plc.
12.2.16. GlaxoSmithKline
12.2.17. Hanmi Pharmaceutical Co., Ltd.
12.2.18. Intas Pharmaceuticals Ltd.
12.2.19. Johnson Johnson
12.2.20. Kyowa Kirin Co., Ltd.
12.2.21. Merck & Co., Inc.
12.2.22. Novartis AG
12.2.23. Partner Therapeutics, Inc.
12.2.24. Pfizer Inc.
12.2.25. Roche
12.2.26. Sanofi
12.2.27. Spectrum Pharmaceuticals, Inc.
12.2.28. Teva Pharmaceutical Industries Ltd.
12.2.29. Viatris Inc.
12.2.30. Others
13. 360 Degree Analyst View
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FEBRILE NEUTROPENIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amneal Pharmaceuticals, Inc.
- AstraZeneca
- Aurobindo Pharma Limited
- Bayer
- Beyond Spring Inc.
- Biocon Biologics Ltd.
- Biogen
- BristolMyers Squibb
- Celgene
- Cellerant Therapeutics, Inc.
- Coherus BioSciences, Inc.
- Eli Lilly and Company
- Fresenius Kabi
- G1 Therapeutics, Inc.
- Gedeon Richter Plc.
- GlaxoSmithKline
- Hanmi Pharmaceutical Co., Ltd.
- Intas Pharmaceuticals Ltd.
- Johnson & Johnson
- Kyowa Kirin Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Partner Therapeutics, Inc.
- Pfizer Inc.
- Roche
- Sanofi
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Others
GLOBAL FEBRILE NEUTROPENIA MARKET, BY ETIOLOGY- MARKET ANALYSIS, 2019 - 2032
- Gram-Negative Bacteria
- Gram-Positive Bacteria
- Fungal Infections
- Viral Infections
GLOBAL FEBRILE NEUTROPENIA MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032
- Empirical Antibiotic Therapy
- Targeted Antibiotic Therapy
- Supportive Care
GLOBAL FEBRILE NEUTROPENIA MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032
- Chemotherapy-Induced Neutropenia
- Transplant-Related Neutropenia
- Genetic Disorders
GLOBAL FEBRILE NEUTROPENIA MARKET, BY DIAGNOSTIC METHODS- MARKET ANALYSIS, 2019 - 2032
- Blood Cultures
- Imaging Tests
- Bone Marrow Aspiration
GLOBAL FEBRILE NEUTROPENIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
